Screen Readers Skip to Content

AFQ056 Drug May Treat Fragile X

Published: 2011-01-09 - Updated: 2022-07-13
Author: Rush University Medical Center | Contact: rush.edu
Peer-Reviewed Publication: Yes
Additional References: Pharmaceutical Information Publications

Synopsis: Fragile X affects 1 in 4000 males and 1 in 6000 females of all races and ethnic groups. It is the most common single gene cause of autism or autistic-like behaviors. Fragile X affects 1 in 4000 males and 1 in 6000 females of all races and ethnic groups. It is the most common single gene cause of autism or "autistic-like" behaviors. The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise, according to a new study.

advertisements

Definition

Fragile X Syndrome

Fragile X syndrome is defined as a genetically inherited form of mental retardation. The syndrome occurs when there is a change or mutation in a single gene, referred to as the 'Fragile X Mental Retardation 1 (FMR1) Gene.' The gene usually produces a protein a person's body requires for their body to develop; however, when there is a change in this gene, the person's body has only a tiny amount of the protein or none of it. This can cause symptoms of Fragile X. Fragile X may be passed from a parent to a child. Parents may have children with the syndrome, even if the parents themselves do not have the syndrome.

Main Digest

The first drug to treat the underlying disorder instead of the symptoms of Fragile X, the most common cause of inherited intellectual disability, shows some promise, according to a new study published in the January issue of Science Translational Medicine. Rush University Medical Center researchers helped design the study and are now participating in the larger follow-up clinical trial.

Related Publications:

The data from the early trial of 30 Fragile X patients found the drug, called AFQ056, made by Novartis Pharmaceuticals, helped improve symptoms in some patients. Patients who had the best response have a kind of "fingerprint" in their DNA that could act as a marker to determine who should get treatment.

"This is an exciting development. It is the first time we have a treatment targeted to the underlying disorder, as opposed to supportive treatment of the behavioral symptoms, in a developmental brain disorder causing intellectual disability. This drug could be a model for treatment of other disorders such as autism," said pediatric neurologist Dr. Elizabeth Berry-Kravis, a study author and director of the Fragile X Clinic and Research Program and the Fragile X-Associated Disorders Program at Rush.

The drug is designed to block the activity of mGluR5, a receptor protein on brain cells involved in most aspects of normal brain function, including regulation of the strength of brain connections, a key process required for learning and memory. Fragile X patients have a mutation in a single gene, known as Fragile X Mental Retardation-1 or FMR1. The mutation prevents FMR1 from making its protein, FMRP, so FMRP is missing in the brain. FMRP normally acts as a blocker or "brake" for brain cell pathways activated by mGluR5. When FMRP is missing, mGluR5 pathways are over-active resulting in abnormal connections in the brain and the behavioral and cognitive impairments associated with Fragile X.

The research team, led by Sebastien Jacquemont of Vaudois University in Switzerland in collaboration with Baltazar Gomez-Mancilla of Novartis, found no significant effects of treatment when the entire group of 30 patients was analyzed. However, in a subsequent analysis, seven patients with a fully methylated gene, which was fully shut down, presumably resulting in no FMR protein in the blood or brain, showed significant improvement in behavior, hyperactivity, and inappropriate behavior speech with the treatment compared to placebo.

"The treatment period in this pilot study was concise, and longer treatment might have been needed to see improvement in the whole group of patients. Importantly, the drug was well-tolerated, and there were no safety problems," said Berry-Kravis.

A larger drug study will recruit 160 patients worldwide and test the effects of a longer treatment period. Rush University Medical Center is one of the participating sites.

Fragile X affects 1 in 4000 males and 1 in 6000 females of all races and ethnic groups. It is the most common single gene cause of autism or "autistic-like" behaviors. Symptoms can also include characteristic physical and behavioral features and speech and language development delays. The impairment can range from learning disabilities to more severe cognitive and intellectual disabilities.

Also See:

Reference Source(s):

AFQ056 Drug May Treat Fragile X | Rush University Medical Center (rush.edu). Disabled World makes no warranties or representations in connection therewith. Content may have been edited for style, clarity or length.

Post to Twitter Add to Facebook

Disabled World is an independent disability community established in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative news, reviews, sports, stories and how-tos. You can also connect with us on Twitter and Facebook or learn more about Disabled World on our about us page.

advertisements

Disabled World provides general information only. The materials presented are never meant to substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Financial support is derived from advertisements or referral programs, where indicated. Any 3rd party offering or advertising does not constitute an endorsement.


Cite This Page (APA): Rush University Medical Center. (2011, January 9). AFQ056 Drug May Treat Fragile X. Disabled World. Retrieved December 3, 2022 from www.disabled-world.com/medical/pharmaceutical/fragile-x-drug.php

Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/fragile-x-drug.php">AFQ056 Drug May Treat Fragile X</a>